Complex Karyotype Newly Defined: the Strongest Prognostic Factor in Advanced Childhood Myelodysplastic Syndrome
Overview
Authors
Affiliations
To identify cytogenetic risk factors predicting outcome in children with advanced myelodysplastic syndrome, overall survival of 192 children prospectively enrolled in European Working Group of Myelodysplastic Syndrome in Childhood studies was evaluated with regard to karyotypic complexity. Structurally complex constitutes a new definition of complex karyotype characterized by more than or equal to 3 chromosomal aberrations, including at least one structural aberration. Five-year overall survival in patients with more than or equal to 3 clonal aberrations, which were not structurally complex, did not differ from that observed in patients with normal karyotype. Cox regression analysis revealed the presence of a monosomal and structurally complex karyotype to be strongly associated with poor prognosis (hazard ratio = 4.6, P < .01). Notably, a structurally complex karyotype without a monosomy was associated with a very short 2-year overall survival probability of only 14% (hazard ratio = 14.5; P < .01). The presence of a structurally complex karyotype was the strongest independent prognostic marker predicting poor outcome in children with advanced myelodysplastic syndrome.
Two cases of AMeD syndrome with isochromosome 1q treated with allogeneic stem cell transplantation.
Kagajo M, Moritani K, Iwamoto M, Miyamoto M, Imai T, Hamada M Leuk Res Rep. 2024; 22:100476.
PMID: 39211293 PMC: 11359758. DOI: 10.1016/j.lrr.2024.100476.
The role of genetic factors in pediatric myelodysplastic syndromes with different outcomes.
Li Y, Cheng L, Peng Y, Wang L, Zhang W, Yin Y BMC Pediatr. 2024; 24(1):28.
PMID: 38191334 PMC: 10773107. DOI: 10.1186/s12887-023-04492-2.
Role of the pioneer transcription factor GATA2 in health and disease.
Aktar A, Heit B J Mol Med (Berl). 2023; 101(10):1191-1208.
PMID: 37624387 DOI: 10.1007/s00109-023-02359-8.
Erlacher M, Andresen F, Sukova M, Stary J, De Moerloose B, Van Der Werff Ten Bosch J Haematologica. 2023; 109(2):422-430.
PMID: 37584291 PMC: 10828767. DOI: 10.3324/haematol.2023.283591.
Pennella C, Cassina T, Rossi J, Baialardo E, Rubio P, Deu M Cancers (Basel). 2022; 14(13).
PMID: 35805057 PMC: 9265690. DOI: 10.3390/cancers14133286.